EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access

Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi‐Centre Matched Analysis

Mohamed H Eldesouki iD, Ahmed Ibrahim iD, Muhammed M Marey, Fadi F Francis, Saqr Alsakarneh, Ernesto Ayala, Aasma Shaukat, Francis A Farraye, Jana G Hashash

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70779 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Mohamed H Eldesouki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, New York Medical College at Saint Michael's Medical Center, Newark, New Jersey, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases, Myeloproliferative Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inflammatory bowel disease (IBD) and myeloproliferative neoplasms (MPNs) share chronic inflammation and immune dysregulation.

Aim

We evaluated the incidence of MPNs among patients with IBD and clinical outcomes of IBD–MPN coexistence.

Methods

Two retrospective cohort analyses were conducted using the TriNetX database. First, adults with ulcerative colitis (UC) or Crohn's disease (CD) were compared with matched non‐IBD controls to estimate incident MPN risk. A coexistence second analysis included patients with UC or CD who developed MPNs and then were matched to IBD without MPN controls to assess 5‐year outcomes, including IBD‐related complications, surgical interventions, colorectal cancer (CRC) and primary sclerosing cholangitis (PSC). Medication subgroup analyses were performed to evaluate associations with MPN risk.

Results

After matching, 3873 patients with UC–MPN and 3474 patients with CD–MPN were included. Compared with matched non‐IBD controls, incident MPN risk was higher in UC (HR 1.60, p = 0.01) and CD (HR 1.56, p < 0.001). In CD, MPN coexistence was associated with higher risks of CRC (HR 1.52, p = 0.012), intestinal fistula (HR 2.84, p < 0.001), obstruction (HR 2.05, p < 0.001), perforation (HR 2.37, p < 0.001), small bowel resection (HR 3.69, p < 0.001) and colectomy (HR 2.10, p < 0.001). In UC, MPN coexistence was associated with higher risks of CRC (HR 1.50, p = 0.001), PSC (HR 1.75, p = 0.03) and pouchitis (HR 1.68, p = 0.003). Exposure to thiopurines (HR 1.28, p < 0.001) was associated with increased MPN risk, whereas TNF, IL‐23 and JAK inhibitors were not.

Conclusions

IBD is associated with increased MPN risk, and IBD–MPNs coexistence is associated with worse IBD‐related complications and malignancy risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesMyeloproliferative DisordersAdultAgedFemaleHumansMaleMiddle AgedIncidenceRetrospective StudiesRisk Factors

Stichwörter der Autor:innen

Crohn's diseaseJanus kinase inhibitorsanti–TNF therapycolorectal cancerinflammatory bowel diseasemyeloproliferative neoplasmsthiopurinesulcerative colitis

Autor:innen und Institutionen

  • Department of Internal Medicine, New York Medical College at Saint Michael's Medical Center, Newark, New Jersey, USA.
  • Division of Gastroenterology & Hepatology, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Department of Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
  • Division of Gastroenterology & Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
  • Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Haematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA.

ORCID-Profile: Mohamed H Eldesouki, Ahmed Ibrahim

Zitieren

APA

Eldesouki, M. H., Ibrahim, A., Marey, M. M., Francis, F. F., Alsakarneh, S., Ayala, E., Shaukat, A., Farraye, F. A., & Hashash, J. G. (2026). Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi‐Centre Matched Analysis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70779

Vancouver

Eldesouki MH, Ibrahim A, Marey MM, Francis FF, Alsakarneh S, Ayala E, et al. Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi‐Centre Matched Analysis. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70779

BibTeX
@article{Eldesouki2026,
  author = {Eldesouki, Mohamed H and Ibrahim, Ahmed and Marey, Muhammed M and Francis, Fadi F and Alsakarneh, Saqr and Ayala, Ernesto and Shaukat, Aasma and Farraye, Francis A and Hashash, Jana G},
  title = {Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi‐Centre Matched Analysis},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70779}
}
Kostenlos starten →